Division Highlights - Hematology, Oncology & Bone Marrow Transplant
The Division of Hematology, Oncology & Bone Marrow Transplant provides state-of-the-art integrated therapies, including stem cell transplant, aimed at curing malignancies and treating hematological disorders in children.
Research interests include ways to recognize and destroy cancer cells using immunologic, cellular and molecular biologic pathways, bone marrow transplantation as immunotherapy, cancer survivorship, neuro-oncology and palliative care.
- Six faculty and scientists (Paul Sondel, MD, PhD; Kenneth DeSantes, MD; Christian Capitini, MD; Mario Otto, MD, PhD; Alexander Rakhmilevich, MD, PhD; and Jacquelyn Hank, PhD) were named to a national pediatric cancer research “Dream Team” charged with developing new therapies for high-risk childhood cancers.
- The Midwest Athletes for Childhood Cancer (MACC) Fund approved a two-year, $800,000 research grant package that includes support for separate projects by Kenneth DeSantes, MD; Christian Capitini, MD; Mario Otto, MD, PhD; Alexander Rakhmilevich, MD, PhD; Jacquelyn Hank, PhD, Emery Bresnick, PhD, and Paul Sondel, MD, PhD.
- Matthew Kutz, a medical student and Shapiro Summer Research Fellow working in the laboratory of Christian Capitini, MD, was awarded a $5,000 St. Baldrick’s Summer Fellowship for his project, “Monitoring of 19F-Labeled NK Cell Trafficking for Cancer Immunotherapy Using MRI.”
- Kenneth DeSantes, MD, and Diane Puccetti, MD, received UW Health Physician Excellence Awards in 2013. Dr. DeSantes received a Clinical Practice Excellence Award and Dr. Puccetti received a Clinical Educator Excellence Award.
- Mario Otto, MD, PhD, received a $2,500 educational grant from Miltenyi Biotec, Inc. to support travel to the CliniMACS Prodigy Launch Meeting in Bergisch Gladbach, Germany.
In addition, Megan McElreath, a research assistant in Dr. Otto’s laboratory, received a 2013-2014 Wisconsin Hilldale Undergraduate/Faculty Research Fellowship.
- Paul Sondel, MD, PhD, and his research team received a $250,000 grant from Hyundai Hope On Wheels and Madison-area Hyundai dealers. The award will support the lab’s research on immunotherapy for the treatment of neuroblastoma. Dr. Sondel also received a $50,000 grant from the UW Institute for Clinical and Translational Research (UW-ICTR) type 1 pilot grant program for his project, “In Depth Delineation of FcyRIIc and FcyRIIIa Genotypes and Potential Clinical Implications.”
In addition, Emily Phillips, a research assistant in Dr. Sondel’s laboratory, received a 2013-2014 Wisconsin Hilldale Undergraduate/Faculty Research Fellowship.
Professor and Division Chief
Associate Professor (CHS)
Associate Professor (CHS)
Assistant Professor (CHS)
Assistant Professor (CHS)
Associate Professor (CHS)
Alderson KL, Erbe A, Boyden M, Sondel PM. Clinical development of antibody fusion proteins for cancer therapy. In: Rosenblatt J, Podack E, Barber GN, Ochoa A, eds. Advances in Tumor Immunobiology and Immunotherapy. New York: Springer; 2013: 213-236.
Baiu DC, Brazel CS, Bao Y, Otto M. Interactions of iron oxide nanoparticles with the immune system: challenges and opportunities for their use in nano-oncology. Curr Pharm Des. 2013;19(37):6606-21. PMID: 23621531.
Bhatia R, Rowley HD, Mosher JC, Alsheik NH, Aagaard-Kienitz B, Diamond CD, Iskandar BJ, Peters A, Boriosi JP, Patel NJ. Extensive sinovenous thrombosis and hemorrhagic infarction during therapy for T-cell acute lymphoblastic leukemia. Pediatr Emerg Care. 2013 Jan;29(1):93-7. PMID: 23283276.
Capitini CM, Redmond WL, Shafer-Weaver KA. Professional development session for early career scientists at SITC 2012. J Immunother Cancer 2013:1(6).
Gossai N, Verneris MR, Karras NA, Gorman MF, Patel NJ, Burke MJ. A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD). Bone Marrow Transplant. 2014 Mar;49(3):440-2. Epub 2013 Dec 9. PMID: 24317126.
Hernando D, Cook RJ, Diamond C, Reeder SB. Magnetic susceptibility as a B(0) field strength independent MRI biomarker of liver iron overload. Magn Reson Med. 2013 Jun 25. [Epub ahead of print] PMID: 23801540.
Hoover-Regan M, Becker T, Williams MJ, Shenker Y. Informed consent and research subject understanding of clinical trials. WMJ. 2013 Feb;112(1):18-23. PMID: 23513309.
Lockridge JL, Zhou Y, Becker YA, Ma S, Kenney SC, Hematti P, Capitini CM, Burlingham WJ, Gendron-Fitzpatrick A, Gumperz JE. Mice engrafted with human fetal thymic tissue and hematopoietic stem cells develop pathology resembling chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2013 Sep;19(9):1310-22. Epub 2013 Jun 24. PMID: 23806772.
Maurer BJ, Kang MH, Villablanca JG, Janeba J, Groshen S, Matthay KK, Sondel PM, Maris JM, Jackson HA, Goodarzian F, Shimada H, Czarnecki S, Hasenauer B, Reynolds CP, Marachelian A. Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. Pediatr Blood Cancer. 2013 Nov;60(11):1801-8. Epub 2013 Jun 29. PMID: 23813912.
Qu X, Felder MA, Perez Horta Z, Sondel PM, Rakhmilevich AL. Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model. Int Immunopharmacol. 2013 Dec;17(4):1141-7. Epub 2013 Nov 4. PMID: 24201083.
Shand JC, Qin H, Nasholm N, Capitini CM, Fry TJ. Minor antigen distribution predicts site-specific graft-versus-tumor activity of adoptively transferred, minor antigen-specific CD8 T cells. Biol Blood Marrow Transplant. 2014 Jan;20(1):26-36. Epub 2013 Oct 17. PMID: 24141010.
Van De Voort TJ, Felder MA, Yang RK, Sondel PM, Rakhmilevich AL. Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice. J Immunother. 2013 Jan;36(1):29-40. PMID: 23211623.
Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM. Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival. Cancer Immunol Immunother. 2013 Aug;62(8):1303-13. Epub 2013 May 10. PMID: 23661160.
Our faculty were principal investigators on the following grants during calendar year 2013.
|Principal Investigator||Funding Agency||Title|
|Capitini, Christian Matthew||St Baldricks Foundation||St. Baldrick's Foundation Summer Fellowship Award|
|Capitini, Christian Matthew||American Cancer Society||Monitoring of 19F-Labeled NK Cell Trafficking for Cancer Immunotherapy Using MRI|
|Capitini, Christian Matthew||Midwest Athletes Against Childhood Cancer||Inhibiting STAT1 as a Platform for GVHD Resistance and Preservation of GVL|
|Desantes, Kenneth||Midwest Athletes Against Childhood Cancer||Support for Research Data Management|
|Desantes, Kenneth||Solving Kids Cancer||Reduced Intensity Haploidentical Transplantation with NK Cell Infusion for Pediatric Acute Leukemia and High Risk Solid Tumors|
|Desantes, Kenneth||Midwest Athletes Against Childhood Cancer||Reduced Intensity Haploidentical Transplantation with NK Cell Infusions for Pediatric Acute Leukemia and High Risk Solid Tumors|
|Desantes, Kenneth||Children's Hospital of Philadelphia||COG–AALL1122|
|Desantes, Kenneth||Children's Hospital of Philadelphia||COG Per Case & Specimen Reimbursement|
|Desantes, Kenneth||Children's Hospital of Philadelphia||St. Baldrick's Supplemental Per Case Reimbursement (COG)|
|Desantes, Kenneth||Solving Kids Cancer||Phase I Trial of Ex-Vivo Expanded Haploidentical NK Cells and Hu14.18-IL2 for Children with Relapsed/Refractory Neuroblastoma|
|Desantes, Kenneth||Children's Hospital of Philadelphia||A Phase III Randomized Trial for Patients with de novo AML Using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) for Patients with High Allelic Ratio FLT2/ITD - AAML1031|
|Desantes, Kenneth||Children's Hospital of Philadelphia||AALL07P1 - A Phase II Pilot Trial of Bortezomib (PS-341, VELCADE IND 58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)|
|Desantes, Kenneth||Midwest Athletes Against Childhood Cancer||Alpha/Beta T-Cell Depleted Haploidentical Transplantation with Post-Transplant Zoledronic Acid to Treat Recurrent or Refractory Pediatric Malignancies|
|Desantes, Kenneth||Children's Hospital of Philadelphia||CCOP: COG Per Case Reimbursement|
|Desantes, Kenneth||Children's Hospital of Philadelphia||11 TREO|
|Desantes, Kenneth||Children's Hospital of Philadelphia||PIDTC Per Case Reimbursement|
|Desantes, Kenneth||Children's Hospital of Philadelphia||COG Chair's Grant/Workload Intensity|
|Desantes, Kenneth||Children's Hospital of Philadelphia||A Phase II Study of MLN8237 (IND#102984), a Selective Aurora A Kinase Inhibitor in Children with Recurrent/Refractory Solid Tumors and Leukemias (ADVL0921)|
|Desantes, Kenneth||Children's Hospital of Philadelphia||ANBL0532 CTSU Per Case Reimbursement|
|Diamond, Carol A||CDC Foundation||Universal Data Collection Project for Blood Inhibitor Study|
|Otto, Mario||Midwest Athletes Against Childhood Cancer||Development of Multifunctional Superparamagnetic anti-GD2 Nanoparticles for Simultaneous Molecular Imaging, Cancer Cell Targeting and Drug Delivery|
|Otto, Mario||Alex’s Lemonade Stand Foundation||Development of an Innovative Treatment Strategy for Neuroblastoma and Other Pediatric Tumors: A Novel Phospholipid Ether Analogue and Its Multifunctional Cancer-Targeting Nanoconstruct|
|Puccetti, Diane||Midwest Athletes Against Childhood Cancer||Psychosocial Aspects of Ending Treatment & Long-Term Survival of Pediatric Cancer Patients: A Joint Proposal|
|Puccetti, Diane||OSI Pharmaceuticals, Inc.||OSI 774 206|
|Sondel, Paul||Midwest Athletes Against Childhood Cancer||Neuroblastoma Tumor Escape Variants Modulate MHC Class I Expression in Response to NK- or T Cell- Mediated Immunotherapy|
|Sondel, Paul||St Jude Medical||A Phase I Trial of the Humanized Anti-GD2 Antibody (HU14.18K322A) in Children and Adolescents with Neuroblastoma or Melanoma|
|Sondel, Paul||St Jude Medical||A Safety/Feasibility Trial of the Addition of the Humanized Anti-GD2 Antibody (Hu14.18K322A) With and Without Natural Killer Cells to Chemotherapy in Children and Adolescents with Recurrent / Refractory Neuroblastoma|
|Sondel, Paul||Stand Up To Cancer / St. Baldrick’s Foundation||SU2C Dream Team|
|Sondel, Paul||Hyundai Hope On Wheels||Novel Modification of Anti-GD2 Immunocytokine Design and Delivery Regimens to Augment T-cell Involvement and Boost Anti-Neuroblastoma Efficacy|
|Sondel, Paul||Children's Hospital of Philadelphia||COG Sci. Leadership 2013-14|
|Sondel, Paul||DHHS, PHS, National Institutes of Health||Antitumor Mechanisms of alpha-CD40/CpG-activated Macrophages|
|Sondel, Paul||DHHS, PHS, National Institutes of Health||Clinical Development of HU14.18-IL2 Targeted Therapy|
|Sondel, Paul||DHHS, PHS, National Institutes of Health||The Role of KIR and FcR Genotype in the Efficacy of mAb and IL2 Immunotherapy|
|Sondel, Paul||Wisconsin Alumni Research Foundation||In Vivo Preclinical Analyses of Molecular Variants of TKIs Designed to Prevent Immune Suppression|
|Sondel, Paul||Wisconsin Alumni Research Foundation||In Vitro Analyses of Molecular Variants of TKIs Designed to Prevent Immune Suppression|
|Sondel, Paul||UWMF–UW Medical Foundation||In Depth Delineation of FCIRIIA Genotypes and Potential Clinical Implications|
|Sondel, Paul||Radiation Society of North America||Synergy of Radiation and immunotherapy in the Treatment of Melanoma|
|Sondel, Paul||NCI-Cancer Immunotherapy Trials Network||Cancer Immunotherapy Trials Network Consortium|